EE20/DRSP(YAZ, BAY86-5300) + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Premenstrual Dysphoric Disorder ( PMDD)
Conditions
Premenstrual Dysphoric Disorder ( PMDD)
Trial Timeline
Jan 1, 2009 → Jan 1, 2011
NCT ID
NCT00824187About EE20/DRSP(YAZ, BAY86-5300) + Placebo
EE20/DRSP(YAZ, BAY86-5300) + Placebo is a phase 3 stage product being developed by Bayer for Premenstrual Dysphoric Disorder ( PMDD). The current trial status is completed. This product is registered under clinical trial identifier NCT00824187. Target conditions include Premenstrual Dysphoric Disorder ( PMDD).
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00824187 | Phase 3 | Completed |
Competing Products
5 competing products in Premenstrual Dysphoric Disorder ( PMDD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| paroxetine | Novo Nordisk | Approved | 84 |
| Levonorgestrel/Ethinyl Estradiol | Pfizer | Phase 3 | 76 |
| Levonorgestrel/Ethinyl Estradiol | Pfizer | Phase 3 | 76 |
| Levetiracetam | UCB | Pre-clinical | 20 |
| Drospirenone and ethinyl estradiol + Placebo | Bayer | Pre-clinical | 20 |